Headlines

Viatris Acquires Oyster Point and Famy Life Sciences

PITTSBURGH — Viatris Inc. has acquired Oyster Point Pharma and Famy Life Sciences to establish a Viatris Eye Care Division.

The purchase price for Oyster Point was about $415 million and the price for Famy was about $280 million.

Former Oyster Point Pharma CEO Jeffrey Nau will lead the new division, according to a press release.

Nau said: “We are thrilled to join Viatris and combine with the assets of Famy Life Sciences to form the foundation of the Viatris Eye Care Division. With this combination we are well on our way to expand our portfolio and commercial footprint and create a global eye care leader. We believe that a new leader in the space can meaningfully shape the future of eye care to address the unmet needs of patients with ophthalmic disease and the eye care professionals who take care of them. I would like to personally thank the Oyster Point Pharma team for their hard work and commitment as we join the Viatris family and pursue Viatris’ mission to empower people worldwide to live healthier at every stage of life.”

Viatris CEO Michael Goettler said: “We are starting the year out strong with the closings of our acquisitions of Oyster Point Pharma and Famy Life Sciences, bringing together our collective commercial expertise, scientific capabilities and global infrastructure to create the Viatris Eye Care Division, which has the potential to deliver even more access to patients and showcases the power of our Global Healthcare Gateway. Viatris has created a performance driven, highly engaging and inclusive culture and we are pleased to welcome our talented, new colleagues to our team. We look forward to continuing to execute against our announced strategic objectives in 2023 that we expect will position Viatris for future growth.”

Viatris was created in November 2020 as a result of the merger of Mylan with Pfizer’s Upjohn division, CHEManager notes.

More from the release:

Under the terms of a definitive agreement, Viatris acquired Oyster Point Pharma for approximately $415 million in cash upfront, which includes the $11 per share paid to Oyster Point Pharma stockholders through a tender offer and the repayment of the principal amount of certain debt of Oyster Point Pharma. In addition, each Oyster Point Pharma stockholder received one non-tradeable contingent value right, representing up to an additional $2 per share, or approximately $60 million in the aggregate, contingent upon Oyster Point Pharma’s achieving certain metrics based on full year 2022 performance, which are expected to be determined in the first quarter of 2023.

The aggregate acquisition price for the Famy Life Sciences business is expected to be approximately $280 million.

About Viatris 

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris’ portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines and a variety of over-the-counter consumer products. With approximately 37,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in PittsburghShanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisIncLinkedIn and YouTube.

INVISION Staff

Since launching in 2014, INVISION has won 23 international journalism awards for its publication and website. Contact INVISION's editors at editor@invisionmag.com.

Recent Posts

Blind and Visually Impaired Cyclists Ride in Tandem with Lighthouse Guild and Foreseeable Future Foundation

Join team #NoLimits at the 2024 TD Five Boro Bike Tour on May 5th to…

1 hour ago

Safilo North America Appoints New Leader

Safilo North America announced the appointment of Gabriele Cusani Sodano as President & Chief Commercial…

2 hours ago

NECO Announces Award Recipients for 2024 Commencement

Join NECO's 130th commencement at Boston’s Symphony Hall on May 19, 2024. Celebrate our honorary…

4 hours ago

This Rural Alabama Practice’s Brand Balances Rustic Charm With a Modern Vibe

The palette is earth tones, but the feel is ‘clean and crisp.’

6 hours ago

Candy Color and Collaborations Abound in the Latest Batch of New Releases

From music festivals to across the universe spec style this season has it covered.

6 hours ago

This website uses cookies.